Global Alzheimer's drugs Market Size, Share, Growth Analysis Report - Forecast 2034

Alzheimer's drugs Market Size

The global alzheimer's drugs market size was worth around USD 5.19 Billion in 2024 and is predicted to grow to around USD 13.91 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 10.5% between 2025 and 2034.

The report analyzes the global alzheimer's drugs market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the alzheimer's drugs industry.

Request Free Sample

Alzheimer’s drugs Market: Overview

Alzheimer's disease is a type of dementia which includes a broad group of brain diseases, such as problems with memory, thinking, and behavior for long term. Causes of Alzheimer’s diseases are still unknown. Alzheimer’s symptoms usually grow slowly and get worse over time. It becomes severe, enough to obstruct a patient’s daily activity. Many researchers consider increasing level of a protein called amyloid in the brain as one of the major causes of Alzheimer disease. It may cause the death of the nerve cells. Major risk factor for Alzheimer disease is growing age wherein people aged 65 and older majorly tend to suffer from Alzheimer disease. Additionally, there are also some genetic and some other causes of Alzheimer diseases. At this moment there is no treatment which can stop the growth of the Alzheimer’s disease. But scientist and researchers are working continuously on it. 

According to Center of Disease Control and Prevention (CDC), in 2017 near about 5.5 million Americans were suffering from Alzheimer’s diseases. Alzheimer is considered as the fifth leading cause of death for all adults. The market is mainly driven by the growing occurrence of diseases in developed countries specifically in the Western region. Also, the prevalence of some neurodegenerative diseases such as dementia has grown in the U.S. In addition, growing occurrence of diseases, firm government encouragement for Alzheimer’s drug development and growing alertness about the treatment of Alzheimer ’s disease is resulting into increased demand for Alzheimer’s drugs market.

Furthermore, growing support for psychological care infrastructure from governments in several developing Asia Pacific countries is likely to drive the Alzheimer's drugs market. However, high prices of the advance drugs may create restraints in underdeveloped countries. Awareness about Alzheimer’s disease in developing regions remains restricted that has resulted in unbalanced healthcare systems and obstructive research infrastructure. In Asia Pacific region, growing encouragement for mental care by governments is anticipated to drive the Alzheimer's drugs market in the near future.

Key Insights

• As per the analysis shared by our research analyst, the global alzheimer's drugs market is estimated to grow annually at a CAGR of around 10.5% over the forecast period (2025-2034).
• Regarding revenue, the global alzheimer's drugs market size was valued at around USD 5.19 Billion in 2024 and is projected to reach USD 13.91 Billion by 2034.
• The alzheimer's drugs market is projected to grow at a significant rate due to rising prevalence of alzheimer's disease, increasing aging population, and ongoing advancements in drug research and development.
• Based on Drug class, the Donepezil segment is expected to lead the global market.
• On the basis of Distribution channel, the Hospital Pharmacy segment is growing at a high rate and will continue to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Request Free Sample

Alzheimer’s drugs Market: Growth Drivers

Increasing Research and Development Activity

Advancements in pharmaceutical and healthcare industries have spawned a new wave of research and development activities across the world and this trend is the same for the Alzheimer’s drugs market as well. As the incidence of Alzheimer’s is on the rise pharmaceutical companies are focusing on the development of novel treatments to maximize their revenue potential as instances of these diseases increases on a global level.

Alzheimer’s drugs Market: Restraints

Discontinuation of Clinical Trials to Hamper Alzheimer’s drugs Market growth

Alzheimer’s has been around for quite a while now but there has been no discovery of a definite treatment for the disease and this has led to skepticism around investments in research and development for the same. This skepticism has led to the discontinuation of clinical trials for the development of Alzheimer’s drugs and hence has had a hindering effect on the global Alzheimer’s drugs market growth. This trend is expected to be prevalent over the forecast period.

Alzheimer's drugs Market: Segmentation Analysis

The global alzheimer's drugs market is segmented based on Drug class, Distribution channel, and region.

Based on Drug class, the global alzheimer's drugs market is divided into Donepezil, Galantamine, Rivastigmine, Memantine, Others.

On the basis of Distribution channel, the global alzheimer's drugs market is bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Stores, Others.

Alzheimer's drugs Market: Report Scope

Recent Developments

• In December 2018 – Eli Lilly and Company a leading name in the pharmaceutical industry announced a collaboration with AC Immune to develop a new treatment for Alzheimer’s which will be done by utilizing AC Immune’s Morphomer platform.

Alzheimer’s drugs Market: Regional Landscape

North America region leads the global Alzheimer’s drugs market in terms of revenue and volume share and is projected to follow the same trend over the forecast period. The presence of key pharmaceutical and healthcare companies, rising research and development activity in the region, and increasing investments in the development of treatment for Alzheimer’s are some of the major factors that drive the Alzheimer’s drugs market potential in this region. The increasing aging population in North America is also expected to boost the incidence of Alzheimer’s and this is expected to propel the demand for Alzheimer’s drugs over the forecast period. The United States is anticipated to be the most notable market in this region through 2028. The rising prevalence of Alzheimer’s disease and increasing launches of new Alzheimer’s drugs are expected to be prominent trends driving market growth in the U.S.

Alzheimer's drugs Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the alzheimer's drugs market on a global and regional basis.

The global alzheimer's drugs market is dominated by players like:

• Abbvie Inc.
• AstraZeneca PLC
• Biogen Inc.
• Daiichi Sankyo Company Limited
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Eli Lilly and Company
• H. Lundbeck A/S
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc and Teva Pharmaceutical Industries Limited

The global alzheimer's drugs market is segmented as follows;

By Drug class

• Donepezil
• Galantamine
• Rivastigmine
• Memantine
• Others

By Distribution channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Stores
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America